BiotechTube

Pasireotide sub-cutaneous

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cushing's Disease

Conditions

Cushing's Disease

Trial Timeline

Aug 16, 2011 → Jan 26, 2017

NCT ID
NCT01582061

About Pasireotide sub-cutaneous

Pasireotide sub-cutaneous is a phase 3 stage product being developed by Novartis for Cushing's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01582061. Target conditions include Cushing's Disease.

What happened to similar drugs?

2 of 9 similar drugs in Cushing's Disease were approved

Approved (2) Terminated (1) Active (6)
🔄pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mgNovartisPhase 3
🔄osilodrostat + osilodrostat PlaceboNovartisPhase 3
🔄PasireotideNovartisPhase 3
✅Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + MetforminNovartisApproved
✅Pasireotide + Cabergoline + Pasireotide LARRecordatiApproved
🔄mifepristoneCorcept TherapeuticsPhase 3
🔄MifepristoneCorcept TherapeuticsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01582061Phase 3Completed

Competing Products

18 competing products in Cushing's Disease

See all competitors
ProductCompanyStageHype Score
AZD4017 and prednisolone + Placebo Oral Tablet and prednisoloneAstraZenecaPhase 2
35
pasireotide LAR + SOM230 LAR 30 mg + SOM230 LAR 10 mgNovartisPhase 3
40
osilodrostat + osilodrostat PlaceboNovartisPhase 3
40
OsilodrostatNovartisPhase 2
35
PasireotideNovartisPhase 3
40
Pasireotide s.c. + Sitagliptin + Liraglutide + Insulin + Pasireotide LAR + MetforminNovartisApproved
43
SOM230 s.c.NovartisPhase 2
35
Lu AG13909LundbeckPhase 2
39
OsilodrostatRecordatiPre-clinical
23
Pasireotide + Cabergoline + Pasireotide LARRecordatiApproved
40
osilodrostatRecordatiPhase 2
32
OsilodrostatRecordatiPre-clinical
27
mifepristoneCorcept TherapeuticsPhase 3
37
CORT125134Corcept TherapeuticsPhase 2
32
Cushing's syndrome confirmationCorcept TherapeuticsPre-clinical
15
MifepristoneCorcept TherapeuticsPhase 3
37
mifepristoneCorcept TherapeuticsPhase 3
37
mifepristoneCorcept TherapeuticsPhase 3
29